Last reviewed · How we verify
Camrelizumab Plus Chemotherapy
Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses.
Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses. Used for Non-small cell lung cancer (NSCLC) in combination with chemotherapy, Nasopharyngeal carcinoma in combination with chemotherapy, Esophageal squamous cell carcinoma in combination with chemotherapy.
At a glance
| Generic name | Camrelizumab Plus Chemotherapy |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and restores cytotoxic T cell function against cancer cells. When combined with chemotherapy, the immunological priming from chemotherapy is enhanced by the checkpoint inhibition, improving overall anti-tumor efficacy.
Approved indications
- Non-small cell lung cancer (NSCLC) in combination with chemotherapy
- Nasopharyngeal carcinoma in combination with chemotherapy
- Esophageal squamous cell carcinoma in combination with chemotherapy
Common side effects
- Fatigue
- Nausea
- Decreased appetite
- Immune-related pneumonitis
- Immune-related hepatitis
- Diarrhea
- Anemia
Key clinical trials
- Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer (PHASE2)
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (PHASE3)
- Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE3)
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (PHASE2)
- Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer (PHASE2)
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab Plus Chemotherapy CI brief — competitive landscape report
- Camrelizumab Plus Chemotherapy updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI